TIGIT Protein, Human, Recombinant (hFc)

TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy

规格	价格/CNY		数量
50 μg	￥ 1,960	现货
100 μg	￥ 3,480	5日内发货
200 μg	￥ 6,150	5日内发货
500 μg	￥ 13,020	5日内发货

规格

价格/CNY

货期

数量

50 μg

￥ 1,960

现货

100 μg

￥ 3,480

5日内发货

200 μg

￥ 6,150

5日内发货

500 μg

￥ 13,020

5日内发货

生物活性

1. Immobilized human CD155a-His at 10μg/mL (100μL/well) can bind human TIGIT-Fc, the EC50 of human TIGIT-Fc is 0.03-0.2μg/mL. 2.Loaded Recombinant Human TIGIT Protein, hFc Tag on ProA Biosensor, can bind Recombinant Human CD155/PVR Protein, His Tag with an affinity constant of 0.18 uM as determined in BLI assay (Routinely tested).

TargetMol Bioactive

产品描述

种属	Human
表达系统	HEK293
标签	hFc
蛋白编号	Q495A1-1
别名	WUCAM, VSTM3, VSIG9, T cell immunoreceptor with Ig and ITIM domains
蛋白构建	A DNA sequence encoding the human TIGIT (NP_776160.2) (Met1-Pro141) was expressed with the Fc region of human IgG1 at the C-terminus.
蛋白纯度	≥ 95% as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
分子量	Approxiamtely 39.2 kDa

内毒素	< 1.0 EU per μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from sterile PBS,pH7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
复溶方法	A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
存储	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	TIGIT, also known as V-set and transmembrane domain-containing protein 3 (VSTM3) or V-set and immunoglobulin domain-containing protein 9 (VSIG9) is a new surface protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on regulatory, memory, activated T cells and NK cells. It binds PVR with high affinity, and PVRL2 with lower affinity, but not PVRL3. Knockdown of TIGIT with siRNA in human memory T cells did not affect T cell responses, however, TIGIT inhibits NK cytotoxicity directly through its ITIM. TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. The binding of PVR to TIGIT on human dendritic cells enhanced the production of IL-1 and diminished the production of IL-12p4. Also, TIGIT counter inhibits the NK-mediated killing of tumor cells and protects normal cells from NK-mediated cytotoxicity thus providing an "alternative self" mechanism for MHC class I inhibition.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint TargetsImmunotherapyTargeted Therapy